A Phase I Study of ABT-888 in Combination With Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas.

Trial Profile

A Phase I Study of ABT-888 in Combination With Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 May 2017

At a glance

  • Drugs Veliparib (Primary) ; Cyclophosphamide
  • Indications Chronic lymphocytic leukaemia; Lymphoma; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 05 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov. (NCT01445522)
    • 05 Jul 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov. (NCT01445522)
    • 05 Jul 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov. (NCT01445522)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top